WaveMan
WaveMan · Company
PAHC · Phibro Animal Health Corp
> Search tickers & screens ⌘K
LIVE
← All companies

PAHC Phibro Animal Health (PAHC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001069899
Quote by TradingView
Form 144 · 7
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
117
13F, latest reported quarter

What the filings say about PAHC

Insiders, 180 days
-$1.1M net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$12.5M
7 notices

Phibro Animal Health insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PHIBRO ANIMAL HEALTH CORP insiders sold a net $1.1M of stock across 126 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
CORCORAN E THOMAS
Director
BUY
2026-06-02 SECtraded 2026-05-29
10,000
$317.7K
+22.8%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Feb 24, 2025.
  • +11.1% median (+6.2% mean) 90-day return after 3 previous buys.
  • The trade is 24.1% of the 41,459 shares held after it.
  • No other insider bought within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CORCORAN E THOMAS bought about $317.7K of PAHC on May 29, 2026, the largest insider purchase at the company on our record; 117 funds added in the latest 13F quarter.
BENDHEIM JACK
President and CEO
SELL
2026-05-07 SEC
2,029
$99.8K
-2.0%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (62 sales), the last on May 6, 2026.
  • The trade is 3.6% of the 56,152 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO BENDHEIM JACK sold about $99.8K of PAHC on May 7, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
BENDHEIM JACK
President and CEO
SELL
2026-05-07 SEC
1,149
$55.5K
-2.0%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (62 sales), the last on May 6, 2026.
  • The trade is 2.0% of the 58,181 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO BENDHEIM JACK sold about $55.5K of PAHC on May 7, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
BENDHEIM JACK
President and CEO
SELL
2026-05-07 SEC
1,350
$64.2K
-2.0%
Context
  • 62 earlier Form 4 trades (code P or S) here by this insider (62 sales), the last on May 6, 2026.
  • The trade is 2.3% of the 59,330 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO BENDHEIM JACK sold about $64.2K of PAHC on May 7, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
BENDHEIM JACK
President and CEO
SELL
2026-05-07 SECtraded 2026-05-06
5,634
$322.2K
-2.0%
Context
  • 60 earlier Form 4 trades (code P or S) here by this insider (60 sales), the last on May 5, 2026.
  • The trade is 9.1% of the 62,086 shares held after it.
  • 1 other insider sold within 30 days.
  • 117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO BENDHEIM JACK sold about $322.2K of PAHC on May 6, 2026; 1 other insider sold within 30 days and 117 funds added in the latest 13F quarter.
126 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 121 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.1M over 180 days
-$1.4M of it by a 10%+ holder
below 63% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
117 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
+17.1% year over year
more than 65% of Pharma & Biotech
Margin
6.6% net margin
more than 77% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
4.9% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch PAHC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.0%12M
-30%-5%+21%+46%2025-102025-122026-022026-042026-062026-082026-10 2026-02-10 · BENDHEIM JACK sold $2.6M2026-02-05 · BFI Co., LLC sold $2.3M2026-02-05 · BFI Co., LLC sold $1.8M2025-11-12 · BFI Co., LLC sold $974.1K2026-02-05 · BFI Co., LLC sold $948.7K2025-11-10 · BFI Co., LLC sold $905.8K2026-02-11 · BENDHEIM JACK sold $720.0K2025-11-10 · BFI Co., LLC sold $632.6K2026-01-21 · BENDHEIM JACK sold $612.2K2026-01-22 · BENDHEIM JACK sold $497.7K2026-04-14 · BFI Co., LLC sold $386.5K2026-03-26 · BENDHEIM JACK sold $383.9K2026-04-22 · BENDHEIM JACK sold $382.2K2026-02-10 · BENDHEIM JACK sold $366.2K2026-02-13 · BFI Co., LLC sold $365.8K2026-02-25 · BFI Co., LLC sold $364.0K2026-04-23 · BENDHEIM JACK sold $357.9K2026-03-31 · BENDHEIM JACK sold $356.0K2026-02-19 · BFI Co., LLC sold $353.8K2026-02-18 · BFI Co., LLC sold $350.6K2026-05-05 · BENDHEIM JACK sold $349.1K2026-03-24 · BENDHEIM JACK sold $344.9K2026-03-30 · BENDHEIM JACK sold $343.9K2026-02-20 · BFI Co., LLC sold $341.3K2026-02-26 · BFI Co., LLC sold $339.7K2026-05-06 · BENDHEIM JACK sold $322.2K2026-05-29 · CORCORAN E THOMAS bought $317.7K2025-11-13 · BFI Co., LLC sold $317.1K2025-11-25 · BFI Co., LLC sold $309.3K2026-04-30 · BENDHEIM JACK sold $305.6K2026-01-13 · BFI Co., LLC sold $304.5K2026-04-21 · BENDHEIM JACK sold $304.2K2026-02-24 · BFI Co., LLC sold $301.9K2026-04-16 · BFI Co., LLC sold $283.2K2026-02-03 · BENDHEIM JACK sold $275.9K2026-03-25 · BENDHEIM JACK sold $275.3K2026-03-17 · BENDHEIM JACK sold $272.8K2026-01-29 · BFI Co., LLC sold $271.7K2026-01-30 · BFI Co., LLC sold $268.3K2026-03-19 · BENDHEIM JACK sold $262.7K2026-03-13 · BENDHEIM JACK sold $258.2K2026-04-28 · BENDHEIM JACK sold $257.4K2026-09-16 · BFI Co. LLC filed to sell $12.4M2026-08-04 · BENDHEIM JACK filed to sell $84.3K2026-08-04 · Bendheim Daniel M filed to sell $17.8K2026-08-04 · David Glenn filed to sell $30.7K2026-08-04 · Escudero Lisa Ann filed to sell $9.7K2026-08-04 · Miller Larry Lee filed to sell $23.2K2026-08-04 · Weinstein Judith filed to sell $17.3K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PAHC: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
3,219,040 sh
$101.1M
FMR LLC
3,160,281 sh
$99.2M
STATE STREET CORP
1,038,382 sh
$32.6M
MILLENNIUM MANAGEMENT LLC
936,701 sh
$29.4M
VANGUARD CAPITAL MANAGEMENT LLC
923,318 sh
$29.0M

Congress trades in PAHC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PAHC planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
BFI Co. LLC
Filed 2026-09-16
$12.4M
BENDHEIM JACK
Filed 2026-08-04
$84.3K
Bendheim Daniel M
Filed 2026-08-04
$17.8K
David Glenn
Filed 2026-08-04
$30.7K
Escudero Lisa Ann
Filed 2026-08-04
$9.7K

PAHC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ranger Micro Cap Fund
$358.2K position · as of 2026-07-31
3.1%
Lord Abbett Focused Small Cap Value Fund
$2.4M position · as of 2026-07-31
2.5%
Hennessy Cornerstone Growth Fund
$8.1M position · as of 2026-07-31
1.7%
Small-Cap Value Series
$5.2M position · as of 2026-05-31
1.3%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$5.5M position · as of 2026-06-30
1.3%
PROFUND VP PHARMACEUTICALS
$143.4K position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$5.2M
$5.2M
$1.5M
+23%
+36%
2024
$5.3M
$5.1M
$1.5M
+11%
-1%
2023
$4.8M
$4.0M
$1.3M
-28%
-3%
2022
$2.9M
$2.9M
$630.1K
-44%
-2%
2021
$3.6M
$3.6M
$803.8K
-24%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.1M sold by insiders over 180 days, 117 funds added last quarter, $12.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PAHC financials

Revenue growth
+17.1%
XBRL, annual
Net margin
6.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.5B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+6.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$9.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.61x
long-term 2026-03-31 plus current 2026-03-31; equity 2026-06-30
Cash flow to debt
0.11x
TTM operating cash flow over long-term 2026-03-31 plus current 2026-03-31
Return on equity
+29.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+7.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+15.8%
operating income after a 27.4% effective tax rate, over long-term 2026-03-31 plus current 2026-03-31 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+17.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
16.00x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
0.15x
P/E over trailing EPS growth of 105%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-06
Revenue$1.5B$1.3B$1.0B$977.9M
Gross profit$512.5M$399.9M$313.1M$298.2M
Operating income$194.4M$110.5M$53.3M$71.8M
Net income$99.7M$48.3M$2.4M$32.6M
EPS (diluted)2.431.190.060.81
Operating cash flow$69.0M$80.1M$87.6M$13.3M
Cash$61.4M$68.0M$70.6M$41.3M
Long-term debtn/a$615.4M$282.3M$311.5M
Dividends paid$19.5M$19.4M$19.4M$19.4M
SEC XBRL, fiscal years, as known on 2026-10-28

PAHC Stock Sonar score 6/7 axes

Find similar shapesCompare

PAHC ranks highest on profitability (80th percentile) and risk and compliance (77th), and lowest on financial health (45th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
80
Inputs
  • Return on equity+29.7% · 91 pct, sector of 545
  • Return on assets+7.0% · 87 pct, sector of 691
  • Return on invested capital+15.8% · 48 pct, sector of 45
  • Return on capital employed+17.3% · 94 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity1.61x · 13 pct, sector of 352
  • Cash flow to debt0.11x · 78 pct, sector of 371
Growth
65
Inputs
  • Revenue growth, YoY+17.1% · 65 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
46
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.1M · 35 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
71
Inputs
  • Funds adding, latest quarter117 · 75 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$710K · 67 pct, sector of 133
Risk and compliance
77
Inputs
  • Short interest, % of float+4.9% · 59 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+2.3% · 94 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PAHC filings, in plain words

Are Phibro Animal Health insiders buying or selling PAHC?

In the 180 days to 2026-10-28, Phibro Animal Health insiders were net sellers, a net $1.1M: $317.7K of purchases and $1.4M of sales reported on Form 4, by 1 buyer and 1 seller.

Are there planned insider sales of PAHC?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $12.5M of stock; the latest, by BFI Co. LLC, was filed 2026-09-16.

Read the full summary

In the 180 days to 2026-10-28, Phibro Animal Health insiders were net sellers of PAHC, a net $1.1M across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Most of that figure, $1.4M, came from a holder of 10% or more rather than an officer or director. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $12.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies